Skip to main content Skip to main navigation menu Skip to site footer

Post-Chemotherapy Monocytopenia as a Predictor of Chemotherapy – Induced Neutropenia in Breast Cancer Patients

  • Azril Okta Ardhiansyah ,
  • IB. Tjakra Wibawa Manuaba ,
  • I Ketut Widiana ,


Abstract

Background: Chemotherapy-induced neutropenia (CIN) is chemotherapy's most frequent myelosuppression effect. Previous studies have examined static prognostic factors to assess dynamic neutrophil changes in each cycle. This study focuses on post-chemotherapy monocytopenia as a more dynamic predictor of CIN. This research aimed to know whether post-chemotherapy monocytopenia can be used as a predictor of CIN in breast cancer patients undergoing the chemotherapy cycle.

Methods: This research used a prospective and a retrospective longitudinal cohort of breast cancer patients undergo a CAF regimen at Sanglah Hospital Denpasar. The research was conducted on 30 samples for three cycles (90 total cycles). Monocyte data is taken in the first week (days 4 to 9), and neutrophil data is taken in the second week (days 10 to 16).

Results: From statistical analysis with interval data scale, we obtained that p 0.001 with Pearson correlation 0.613 for cycle 1, p 0.001 with Pearson correlation 0.611 for cycle 2, and p 0.003 with Pearson correlation 0.522 for cycle 3.

Conclusions: In conclusion, post-chemotherapy monocytopenia can be used to predict the occurrence of chemotherapy-induced neutropenia (CIN) with the strongest positive correlation in the first cycle.

Keywords: Monocytopenia predictor chemotherapy-induced neutropenia Cancer Benign neoplasm of Breast

References

  1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I BF. International Agency for Research on Cancer 2020. Glob Cancer Obs Cancer Today. 2020;419:1–2.
  2. World Health Organization. Cancer Incident in Indonesia. Int Agency Res Cancer. 2020;858:1–2.
  3. Minister of Health of the Republic of Indonesia. Decree of the Minister of Health number: 134/Men.Kes/SK/IV/78 concerning the Organizational Structure and Work Procedures of General Hospitals pasal 4. 1978.
  4. RSUP Sanglah. Laporan Tahunan 2019 RSUP Sanglah Denpasar. 2020. p. 1–70.
  5. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–205.
  6. Keswara A, Sudarsa I, Golden N. THE RISK FACTOR OF NEUTROPENIA ON LOCALLY ADVANCED BREAST CANCER PATIENTS TREATED WITH FIRST CYCLE CYCLOPHOSPHAMIDE, DOXORUBICINE, 5- FLUOROURACIL CHEMOTHERAPY AT SANGLAH GENERAL HOSPITAL DENPASAR, BALI-INDONESIA. Bali Med Journal; Vol 1, No 3. 2012;1(3).
  7. Deylami AA, Hoseinzadeh M, Vosoghi T, Mahdian AA. A comparison of the effects of every day and every other day administration of Granulocyte - colony stimulating factor (G-CSF) on the number of leukocyte, platelets, hemoglobin, and pain in patients with breast cancer. Bali Med J. 2017;6(3):674.
  8. Jenkins P, Freeman S. Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Ann Oncol. 2009;20(1):34–40.
  9. Crawford J, Dale DC, Lyman GH. Chemotherapy-Induced Neutropenia: Risks, Consequences, and New Directions for Its Management. Cancer. 2004;100(2):228–37.
  10. Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol. 2014;90(3):190–9.
  11. Chen K, Zhang X, Deng H, Zhu L, Su F, Jia W, et al. Clinical predictive models for chemotherapy-induced febrile neutropenia in breast cancer patients: A validation study. PLoS One. 2014;9(6).
  12. Hall JE. Guyton and Hall Text Book of Medical Physiology. 13th ed. Philadelphia: Elsevier; 2016.
  13. Barret EK, Barman SM, Brooks HL, Yuan J. Ganong’s Review of medical physiology. 2019th ed. USA: McGraw Hill Education; 2019.
  14. Sato I, Nakaya N, Shimasaki T, Nakajima H, Motoo Y. Prediction of docetaxel monotherapy-induced neutropenia based on the monocyte percentage. Oncol Lett. 2012;3(4):860–4.
  15. Shimanuki M, Imanishi Y, Sato Y, Nakahara N, Totsuka D, Sato E, et al. Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma. Oncotarget. 2018;9(27):18970–84.
  16. Moriyama Y, Horita N, Kudo M, Shinkai M, Fujita H, Yamanaka T, et al. Monocyte nadir is a possible indicator for neutrophil nadir during lung cancer chemotherapy. Vol. 11, Clinical Respiratory Journal. 2017. p. 453–8.
  17. Ouyang W, Liu Y, Deng D, Zhou F, Xie C. The change in peripheral blood monocyte count: A predictor to make the management of chemotherapy-induced neutropenia. J Cancer Res Ther. 2018;14(10):S565–70.
  18. Sobri FB, Azhar Y, Wibisana IGN, Rachman A. Manajemen Terkini Kanker Payudara. Edisi 1. Jakarta: Media Aesculapsius; 2017.
  19. Hosmer W, Malin J, Wong M. Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer. 2011;19(3):333–41.
  20. Suzanna E, Siraqit T, Rahayu PS. Registrasi kanker berbasis rumah sakit di RS kanker Dharmais – Pusat Kanker Nasional 1993 - 2007. Indones J Cancer. 2012;6:1–12.
  21. Azhar Y, Agustina H, Abdurahman M, Achmad D. Breast cancer in west java: where do we stand and go? Indones J Cancer. 2020;14(3):91–6.
  22. Mursyidah NI, Ashariati A, Kusumastuti EH. Comparison of Breast Cancer 3-years Survival Rate Based on the Pathological Stages. JUXTA J Ilm Mhs Kedokt Univ Airlangga. 2019;10(1):38.
  23. Wolff D, Culakova E, Poniewierski MS, Lyman GH, Dale D., Crawford J. Predictors of chemotherapy-induced neutropenia and Its complications: results from a prospective nationwide registry. J Support Oncol. 2005;3:24–5.
  24. Moreau M, Klastersky J, Schwarzbold A, Muanza F, Georgala A, Aoun M, et al. A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol. 2009;20(3):513–9.

How to Cite

Ardhiansyah, A. O., Manuaba, I. T. W., & Widiana, I. K. (2022). Post-Chemotherapy Monocytopenia as a Predictor of Chemotherapy – Induced Neutropenia in Breast Cancer Patients. Bali Medical Journal, 11(3), 1325–1330. https://doi.org/10.15562/bmj.v11i3.2844
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
0

Total
0

Share

Search Panel

Azril Okta Ardhiansyah
Google Scholar
Pubmed
BMJ Journal

IB. Tjakra Wibawa Manuaba
Google Scholar
Pubmed
BMJ Journal

I Ketut Widiana
Google Scholar
Pubmed
BMJ Journal